Outcomes of patients with ER+/HER2+non-metastatic breast cancer treated with trastuzumab without chemotherapy

被引：0
|
作者：
Nguy, Susanna [1 ]
Wu, S. Peter [1 ]
Oh, Cheongeun [1 ]
Gerber, Naamit K. [1 ]
机构：
[1] NYU Langone Med Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-02
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Addition of Tucatinib to Trastuzumab and Chemotherapy Improves Survival for Patients With Metastatic, HER2-Positive Breast Cancer
    Printz, Carrie
    CANCER, 2020, 126 (10) : 2113 - 2113
  • [42] Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
    Podder, Vivek
    Ranjan, Tulika
    Bardhan, Mainak
    McCracken, Andrea
    Hurmiz, Charlie
    Ganiyani, Mohammad Arfat
    Ahmad, Shahzaib
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
    Bruno, R
    Washington, CB
    Lu, JF
    Lieberman, G
    Banken, L
    Klein, P
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (04) : 361 - 369
  • [44] Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
    Rene Bruno
    Carla B. Washington
    Jian-Feng Lu
    Grazyna Lieberman
    Ludger Banken
    Pamela Klein
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 361 - 369
  • [45] DOES PREVIOUS NEOADJUVANT/ADJUVANT TRASTUZUMAB INFLUENCE THE DISEASE OUTCOME OF METASTATIC HER2 POSITIVE BREAST CANCER PATIENTS TREATED WITH FIRST LINE TRASTUZUMAB AND CHEMOTHERAPY
    Milosevic, Snezana
    Stanic, Nemanja
    Bozovic-Spasojevic, Ivana
    Tomasevic, Zorica
    Susnjar, Snezana
    BREAST, 2015, 24 : S41 - S42
  • [46] Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab
    Yuri Torrejon, Davis
    Di Cosimo, Serena
    Sanchez-Olle, Gessami
    Balmana, Judith
    Bellet, Meritxell
    Gomez, Patricia
    Saura, Cristina
    Manuel Perez-Garcia, Jose
    Munoz-Couselo, Eva
    Vidal, Maria
    Ortega, Vanesa
    De Mattos-Arruda, Leticia
    Oliveira, Mafalda
    Mulet-Margalef, Nuria
    Tabernero, Josep
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
    P. S. Blanchette
    D. N. Desautels
    G. R. Pond
    J. M. S. Bartlett
    S. Nofech-Mozes
    M. J. Yaffe
    K. I. Pritchard
    Breast Cancer Research and Treatment, 2018, 170 : 169 - 177
  • [48] Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab
    Blanchette, P. S.
    Desautels, D. N.
    Pond, G.
    Bartlett, J. M. S.
    Nofech-Mozes, S.
    Yaffe, M.
    Pritchard, K. I.
    CANCER RESEARCH, 2017, 77
  • [49] HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab
    O'Malley, Frances P.
    Thomson, Tom
    Julian, Jim
    Have, Cherry
    Crosby, Roxanne
    Gelmon, Karen
    Andrulis, Irene
    Whelan, Tim
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2008, 132 (01) : 61 - 65
  • [50] Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States
    Giovanni Zanotti
    Matthias Hunger
    Julia J Perkins
    Ruslan Horblyuk
    Monique Martin
    BMC Cancer, 17
12345